Related Experiment Video
Updated: Oct 26, 2025
07:08
Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
Published on: February 27, 2018
9.8K
Emerging therapeutics in Huntington's disease
Robert Wiggins1, Andrew Feigin1
1NYU Langone's Fresco Institute for Parkinson's & Movement Disorders, Department of Neurology, United States of America.
Expert Opinion on Emerging Drugs
|July 28, 2021
Summary
Huntington's disease (HD) treatments are advancing, with emerging therapies offering hope despite recent setbacks. Continued research into HD pathophysiology and biotechnology promises impactful treatments for patients and families.
Area of Science:
- Neurodegenerative diseases
- Neurology
- Genetics
Background:
- Huntington's disease (HD) is a neurodegenerative disorder impacting motor, cognitive, and behavioral functions.
- Current clinical practice for HD primarily focuses on symptomatic management due to a lack of curative treatments.
- Recent advancements have spurred optimism for novel disease-modifying therapeutics.
Purpose of the Study:
- To review the current landscape of emerging therapies for Huntington's disease.
- To provide an overview of ongoing research and clinical trials in HD therapeutics.
- To offer an expert perspective on the future of HD treatment development.
Main Methods:
- Conducted a PubMed literature review for pertinent reviews and analyses.
- Utilized ClinicalTrials.gov to identify ongoing and planned clinical trials.
- Reviewed drug manufacturer websites and press releases for up-to-date trial results and information.
Main Results:
- Identified a diverse range of promising emerging therapies for Huntington's disease.
- Highlighted the dynamic nature of the HD therapeutic field.
- Acknowledged recent setbacks in specific research avenues, such as antisense oligonucleotides.
Conclusions:
- Despite setbacks, enthusiasm for novel Huntington's disease therapies remains high.
- Advancements in understanding HD pathophysiology and biotechnology are expected to drive impactful treatments.
- Emerging therapies hold significant promise for improving the lives of patients, families, and caregivers.
Related Concept Videos
01:24Parkinson's Disease: Treatment
569
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
569
01:22Alzheimer's Disease: Treatment
419
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
419
01:15Parkinson's Disease: Overview
990
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
990
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
547
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
547
01:28Drug Therapy
125
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
125
01:16Therapeutic Drug Monitoring: Overview and Classification
50
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
50